January 31, 2017 — Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement offering. The offering was significantly over-subscribed and provides HTL with a strong financial base entering into 2017. The company expects to commence the international launch of its MyoVista product in the first quarter.
Prior to this latest funding round, HTL had previously raised over $21 million in funding. The latest round will fund sales launch, operations and further clinical work. HTL is in the process of hiring sales staff as it prepares for the launch of its MyoVista product.
The MyoVista is a technologically advanced electrocardiography (ECG) device that uses proprietary technology to assist in the early detection of heart disease. It uses standard 12-lead resting ECG protocols to provide both a traditional ECG incorporating interpretive analysis, as well as further proprietary informatics that facilitate the early identification of ischemic and other myocardial dysfunctions.
For more information: www.hearttestlabs.com